Shionogi & Co.

Shionogi & Co., Ltd. is a Japanese pharmaceutical company that focuses on the research, development, manufacturing, and marketing of pharmaceutical products, particularly in the areas of infectious diseases, pain/central nervous system (CNS), and cancer. While its primary function is as an operating company, it also engages in strategic investments. In April 2025, the company established a Corporate Venture Capital (CVC) group to invest in seed, early, and mid-stage startups to identify future growth opportunities. The company also acts as a Limited Partner (LP) through investment agreements with venture capital funds like AN Venture Partners.